How Richard Scolyer made his mark in melanoma research

Richard Scolyer, an acclaimed Australian pathologist and a key figure in melanoma research, passed away on Sunday at the age of 59. His pioneering work significantly contributed to lowering melanoma-related deaths across Australia. Scolyer's dedication extended beyond his research, encompassing diagnostic frameworks now used globally and a profound commitment to teaching and mentoring.

“

Whatever happens, I feel like there will be a legacy from what Georgina, our team and I have tried to do.

Colleagues remember Professor Scolyer as an extraordinary pathologist, often referred to as the 'pathologists' pathologist.' He was known for his exceptional diagnostic skills and his ability to apply decades of experience to complex cases, understanding the critical role of accurate tissue diagnosis in patient care. His passion for medicine began in his teens, leading him to a 15-year path to becoming a specialist pathologist after medical school.

“

The 'pathologists' pathologist', who also made generous time for clinicians navigating complex diagnostic cases, understanding that an accurate tissue diagnosis was critical to patient care.

Early in his career, Scolyer joined Melanoma Institute Australia, balancing research at the University of Sydney with diagnosing melanoma cases at Royal Prince Alfred Hospital. Melanoma, a skin cancer primarily caused by sun exposure, is the third most common cancer in Australia. When Scolyer began his work, surgery was the only treatment, and advanced cases were often fatal.

“

His knowledge was vast, his skill exceptional, with an unparalleled eye for accurate tissue diagnoses, and the precision to apply decades of experience where it mattered most.

Working with a wealth of patient data and tissue samples, Scolyer and his colleagues, including Georgina Long and cancer epidemiologist Anne Cust, advanced the understanding of melanoma's underlying genetic changes. The creation of a large biobank in 1998 was crucial for this research. The rise of immunotherapy drugs in the 2000s, which harness the immune system to fight cancer, marked a significant turning point, with Scolyer describing the early results as a 'penicillin moment' for melanoma treatment. He and Professor Long conducted clinical trials exploring different treatment combinations.

“

Particularly the genetic changes that underpin development of melanoma.